Remitch OD (nalfurafine hydrochloride orally disintegrating tablet) / Toray, Japan Tobacco, Sumitomo Pharma, 3SBio - LARVOL DELTA

KARE-PD: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis (clinicaltrials.gov) - P=N/A | N=93 | Recruiting | Sponsor: Guangdong Provincial People's Hospital | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Chinese PLA General Hospital

New trial • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

ANALYSIS OF THE EFFICACY AND SAFETY OF NALFURAFINE HYDROCHLORIDE FOR TREATING CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS IN HEMODIALYSIS PATIENTS (ISN-WCN 2026) - "Multivariate ordered logistic regression analysis indicated that the frequency of hemodiafiltration was an independent factor associated with the antipruritic efficacy of nalfurafine hydrochloride(OR=0.24, 95%CI 0.06∼0.90, P=0.035). Download: Download high-res image (92KB)Download: Download full-size imageDownload: Download high-res image (302KB)Download: Download full-size imageDownload: Download high-res image (198KB)Download: Download full-size imageDownload: Download high-res image (119KB)Download: Download full-size imageConclusion Nalfurafine hydrochloride effectively relieves pruritus symptoms in HD patients and has a good safety profile."

Clinical • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans (clinicaltrials.gov) - P=N/A | N=72 | Completed | Sponsor: Shandong New Time Pharmaceutical Co., LTD

New trial • Dermatology • Pruritus

KARE-PD: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis (clinicaltrials.gov) - P=N/A | N=93 | Recruiting | Sponsor: Guangdong Provincial People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

KARE-PD: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis (clinicaltrials.gov) - P=N/A | N=93 | Not yet recruiting | Sponsor: Guangdong Provincial People's Hospital

New trial • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Refractory Pruritus in Patients with Non-Dialysis CKD Stages 3-5 (ChiCTR) - P=N/A | N=95 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New trial • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet (clinicaltrials.gov) - P3; N=135; Recruiting; Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Clinical • New P3 trial • Dermatology • Pruritus • Renal Disease